



SDI Review Form 1.6

| | |
|--------------------------|--|
| Journal Name: | International Journal of Medical and Pharmaceutical Case Reports |
| Manuscript Number: | Ms_IJMPCR_26538 |
| Title of the Manuscript: | Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated |
| Type of the Article | Case study |

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|---|--|
| Compulsory REVISION comments | | |
| Minor REVISION comments | <p>Is a report of 2 cases demonstrating that treatments based on older chemotherapy drugs, has a use in treating of multiple myeloma, a common practice in developing countries</p> <p>In both cases, the authors must do a better description of the quality of life that the patient had during the time they received medical treatment, it is important to mention if any scale was used to assess the quality of life.</p> | |
| Optional/General comments | <p>On page 39 the word Mandible should not be written in uppercase letters</p> | |

Reviewer Details:

| | |
|----------------------------------|---|
| Name: | <i>Alberto Olaya-Vargas</i> |
| Department, University & Country | <i>National Institute of Pediatrics , Universidad Nacional Autonoma de Mexico, Mexico</i> |